Haig Keledjian

Haig Keledjian currently serves as the President and CEO. He also serves as Chairman of our Board of Directors, a position he has held since 2001. Mr. Keledjian is the original founder of our Company and has served in various positions with our Company since founding our Company in 2001. He previously oversaw the licensing of our global intellectual property portfolio and guided our research and development program for over 10 years, and now focuses his efforts on expanding our intellectual property portfolio, as well as coordination of ongoing research, collaborator relationships, and fundraising activities.

Mr. Keledjian is a California attorney. Prior to founding our Company, he practiced tax and estate law in California. Mr. Keledjian is a valuable member of our Board of Directors due to his intimate knowledge of our Company as he was our original founder and his extensive strategic and management experience in our industry.

Mr. Keledjian holds a Bachelor of Science in Business and Accounting from California State University Los Angeles, followed by a Master’s Degree in Taxation, from Golden State University in 1985. In 1989, Mr. Keledjian completed his undergraduate law studies by obtaining a B.S. in law from Glendale University and in 1991 obtained his Juris Doctorate from Glendale University. He was admitted to the California State Bar in 1993.

Arthur Keledijan

Arthur Keledjian has served as a member of our Board of Directors since 2001. Mr. Keledjian has been involved with us since our inception and is a valuable addition to our Board of Directors due to his longevity with us and extensive strategic advising experience. Mr. Keledjian is responsible for procuring and managing over $10 million in annual sales with SCI – Hispana in his business development role. He is based in Los Angeles, CA.

Mr. Keledjian graduated from California State University, Los Angeles with a Bachelor of Science in Business Administration & Marketing.

Our Advisors Management Team

Marshall C. Phelps Jr., JD  (advisory board member)

Mr. Phelps is the former Corporate Vice President for Intellectual Property Policy and Strategy for both Microsoft and IBM.

At Microsoft, Mr. Phelps was responsible for establishing global policy and strategy for Microsoft’s intellectual property, and interfacing with governments and technology companies about intellectual property issues. During his tenure at Microsoft, he also oversaw management of the Microsoft’s trademark, copyright, patent, trade secret, and related divisions.

Prior to Microsoft, Mr. Phelps spent 28 years at IBM. He was responsible for intellectual property and licensing, overseeing IBM’s patent licensing program and intellectual property portfolio development.

Mr. Phelps holds a Bachelor of Arts degree from Muskingum College, a Master of Science degree from Stanford Graduate School of Business and a doctorate from Cornell Law School.

Bob Berliner, jd  (advisory board member)

Mr. Berliner was a founding member of the intellectual property firm of Robbins, Berliner & Carson L.L.P. for more than 25 years, becoming a partner of the international general law firm of Fulbright & Jaworski L.L.P. following the 1997 merger of the two firms. Having decades of practice in all aspects of intellectual property, and having developed an extensive network of top rated intellectual property firms in over twenty countries, he founded Berliner & Associates specializing in patent, trademark and copyright prosecution, licensing and litigation, both in the United States and worldwide.

He has close familiarity with the special needs of University patent portfolios and in assisting in the formation and operations of early stage companies. Bob is a member of the Intellectual Property Rights panel of the American Arbitration Association, and has served as arbitrator in significant patent and trade secret disputes.

Mr. Berliner is a founding Director and currently is on the Board of the Southern California Biomedical Council. Mr. Berliner received a B.Sc. in Chemistry in 1956 from The City College of New York and a J.D. in 1960 from Michigan State University. In December 2010 he will receive an Honorary Degree in Humane Letters from the University of Colorado. He is the published author of articles on technology licensing, and other intellectual property topics and has been a panelist or speaker at numerous conferences. Mr. Berliner was admitted to practice law in Michigan in 1961 and in California in 1966. He is also licensed to practice before the Federal District Courts of Central and Southern California, the Court of Appeals for the Ninth Circuit and the Federal Circuit, and the United States Supreme Court. He is a registered Patent Attorney with the United States Patent and Trademark Office.

Dr. Richard Tobin, PHD  (Assistant Scientific Advisor)

Dr. Tobin has been a key figure in researching the Targeted Peptide Technology (TPT) over the past five years under Dr. Newell-Rogers, beginning at the University of Colorado and then at Texas. His thesis was titled, “Functional regulation of MHC class II and B-cell survival by cell surface expression of MHC II in association with CLIP.” He brings to the team a wealth of understanding and know-how as it relates to TPT. Dr. Tobin received his PhD in Medical Sciences from TexasA&M University.

Dr. Jim MacDonald, PHD  (Clinical Advisor)

Dr. MacDonald provides over 40 years of experience working with Merck, Schering-Plough as the head of toxicology departments. He is a key advisor in the design and execution of our IND-enabling program and received his PhD in Toxicology from the University of Cincinnati.

Dr. Shelley Ching, PHD, DVM  (Animal toxicity study advisor)

Dr. Ching provides over 20 years of experience as a pathologist and animal toxicity program manager. She is an expert in navigating the language and process of Clinical Research Organizers, or CROs, as well as assessing and critiquing protocol details to maximize the value of each of our studies. She received her PhD in Pathology from Colorado State University and her DVM from the University of Georgia.

Dr. John Stubbs, PHD  (Animal toxicity study advisor)

Dr. Stubbs provides over 35 years of experience with Beecham and Merck, Merck, and Johnson & Johnson. He advises us regarding design and assessment of the LCMS-MS assay, as well as pharmacokinetic data produced by our third party animal toxicity group. He received his PhD in Bioanalytical Chemistry and Drug Metabolism from the University of London’s School of Pharmacy.

Dr. Russ Hensel, PHD  (Animal toxicity study advisor)

Dr. Hensel provides over 30 years of experience with Rhone-Poulenc Rorer, Covance Laboratories, Johnson & Johnson, and Tandem Labs. He designs and assesses pharmacokinetic data produced by our third party animal toxicity group. He received his PhD in Analytical Chemistry from Drexel University.

Dr. Catherine Strader, PHD  (clinical advisor)

Dr. Strader provides over 35 years of experience working with Merck, Schering-Plough as a Senior Vice President of Science and Technology. She is instrumental in identifying and engaging the critical paths to advancing VG1177 from a concept to treatment.

Dr. Gary Musso, PHD  (corporate advisor)

Dr. Musso provides over 25 years of experience with Big Pharma at Salk Institute of Biotechnology, Alkermes Inc., Praecis Pharmaceutics, and Proteolix/Only Pharmaceuticals. He designed a suitable formulation that can be taken into clinical trials and advises us in general capacities. He received his PhD in Bio-Organic Chemistry from the University of Chicago.

Board of Directors Management Team

Dr. M. Karen Newell-Rogers  chief scientist

Dr. Newell-Rogers is our Chief Scientist and the primary inventor of both Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). She is the Raleigh R. White, Jr. Endowed Professor of Surgical Research, Department of Surgery, College of Medicine, at Texas A&M Health Sciences Center and Scott and White Hospital in Temple, Texas. Dr. Newell-Rogers is also the Director of the newly formed Center for Cell Death and Differentiation at TAMHSC/Scott and White Hospital.

Newell-Rogers was formerly at the University of Colorado, Colorado Springs, as Scientific Director of the CU Institute of Bioenergetics and Immunology and as the Clement and Margaret Markert Endowed Professor of Biology. She has authored or co-authored several dozen peer-reviewed papers predominantly focused on immunology and cellular metabolism, and she holds over 30 issued or pending patents.

Mr. Haig Keledijian  vice president of research & development, secretary

Haig Keledjian currently serves as our Vice President of Research and Development and Secretary, a position he has held since July 2013. He also serves as Chairman of our Board of Directors, a position he has held since 2001. Mr. Keledjian is the original founder of our Company and has served in various positions with our Company since founding our Company in 2001, including previously serving as our Chief Executive Officer. He previously oversaw the licensing of our global intellectual property portfolio and guided our research and development program for over 10 years, and now focuses his efforts on expanding our intellectual property portfolio, as well as coordination of ongoing research, collaborator relationships, and fundraising activities.

Mr. Keledjian is a California attorney. Prior to founding our Company, he practiced tax and estate law in California. Mr. Keledjian is a valuable member of our Board of Directors due to his intimate knowledge of our Company as he was our original founder and his extensive strategic and management experience in our industry.

Mr. Keledjian holds a Bachelor of Science in Business and Accounting from California State University Los Angeles, followed by a Master’s Degree in Taxation, from Golden State University in 1985. In 1989, Mr. Keledjian completed his undergraduate law studies by obtaining a B.S. in law from Glendale University and in 1991 obtained his Juris Doctorate from Glendale University. He was admitted to the California State Bar in 1993.

Board of Directors Our Advisors